# STAR-TREC: HCP commentary report

> 303 verified statements (75 from clinicians verified by NPI or staff page) from 79 commentary sources · 11 findings · updated Oct 31, 2026

## Report

- Trial: STAR-TREC: Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?
- NCT ID: NCT02945566
- Registry: https://clinicaltrials.gov/study/NCT02945566
- Sponsor: University of Birmingham
- Phase: Phase 2/Phase 3
- Status: Active, not recruiting
- Drugs tested: none (the trial tests no drug)
- Indication: early rectal cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-10-31
- Last checked: 2026-10-31
- Release hash: a479f9459d32fb125ae569431eba4a61fc2b9834d6b3b3d6ac60e763ee282234

## Counts

- HCP commentary sources screened: 160
- Sources cited by verified statements: 84
- Verified statements: 303
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 75
- Findings: 11
- Named people in screened sources (unnamed speakers and accounts not counted): 58
- Voices cited: 56
- Cited voices identity-verified: 40
- Organisational or shared accounts (not counted as people): 11

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

Clinician commentary on STAR-TREC in the sources reviewed for this edition leads to one open question: What evidence and service capability are needed to discuss selective organ preservation confidently without overstating long-term safety or dismissing access-dependent alternatives? Its leading findings: (1) the early long-course advantage is not read as proof of equivalent cancer control. (2) short-course criticism reaches treatment and trial-participation decisions, but dissent is setting-specific. (3) selection, response assessment and capacity for surveillance define the opportunity. 8 more findings follow. 160 sources screened, 84 cited; not all HCPs or all public discussion.

## Open Medical Affairs question

What evidence and service capability are needed to discuss selective organ preservation confidently without overstating long-term safety or dismissing access-dependent alternatives?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The early long-course advantage is not read as proof of equivalent cancer control
- F2. Short-course criticism reaches treatment and trial-participation decisions, but dissent is setting-specific
- F3. Selection, response assessment and capacity for surveillance define the opportunity
- F4. Avoiding surgery is not a substitute for knowing pelvic function and treatment harms
- F5. Mesorectal-only fields are themselves a perceived innovation, with clinical and planning caveats
- F6. Convenience and access sustain interest in shorter treatment, but cost and sequencing are contested
- F7. Dose escalation and contact brachytherapy attract strong support, qualified by size, evidence interpretation and access
- F8. Alternative regimens and added immunotherapy remain questions rather than established improvements
- F9. Preoperative schedule evidence is not treated as a complete answer for definitive organ preservation
- F10. Patient-preference design and recruitment earn praise, while enthusiasm may outrun maturity
- F11. Patient stories give organ preservation meaning, but public descriptions can overgeneralize

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 13 | 12 | 8 | 5 | recorded | 3 |
| F2 | 11 | 12 | 2 | 4 | recorded | 3 |
| F3 | 12 | 12 | 8 | 8 | recorded | 3 |
| F4 | 9 | 6 | 3 | 4 | recorded | 3 |
| F5 | 13 | 10 | 5 | 5 | recorded | 3 |
| F6 | 7 | 7 | 3 | 5 | recorded | 3 |
| F7 | 11 | 13 | 4 | 5 | recorded | 3 |
| F8 | 11 | 11 | 6 | 8 | recorded | 3 |
| F9 | 14 | 13 | 1 | 5 | recorded | 3 |
| F10 | 15 | 15 | 12 | 9 | recorded | 3 |
| F11 | 20 | 12 | 9 | 5 | recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 7 | 2 | 0 | 2 | 2 | 16 | 0 | 4 posts and articles, 3 podcasts and video, 1 registry | yes |
| F2 | 11 | 0 | 0 | 0 | 0 | 11 | 1 | 2 posts and articles | yes |
| F3 | 9 | 1 | 0 | 0 | 2 | 13 | 0 | 6 posts and articles, 1 podcast or video, 1 publication | yes |
| F4 | 3 | 3 | 1 | 0 | 2 | 11 | 0 | 2 posts and articles, 1 podcast or video | yes |
| F5 | 6 | 3 | 0 | 1 | 3 | 13 | 1 | 2 posts and articles, 2 podcasts and video, 1 publication | yes |
| F6 | 4 | 1 | 0 | 2 | 0 | 7 | 0 | 2 posts and articles, 1 podcast or video | yes |
| F7 | 5 | 1 | 2 | 1 | 2 | 13 | 1 | 3 posts and articles, 1 podcast or video | yes |
| F8 | 6 | 3 | 0 | 2 | 0 | 12 | 0 | 5 posts and articles, 1 podcast or video | yes |
| F9 | 4 | 0 | 0 | 0 | 10 | 15 | 4 | 1 post or article | yes |
| F10 | 6 | 3 | 2 | 0 | 4 | 17 | 0 | 9 posts and articles, 1 podcast or video, 1 publication, 1 registry | yes |
| F11 | 7 | 2 | 1 | 1 | 9 | 20 | 0 | 5 posts and articles, 4 podcasts and video | yes |

### Trial dimensions

- Primary endpoint: Phase II (Feasibility study) Primary Outcome: Recruitment Rate: F10 (3 shared claims)
- Primary endpoint: Phase III Primary Outcome: Organ Preservation: F1 (10 shared claims), F3 (4 shared claims), F8 (1 shared claims), F10 (3 shared claims), F11 (1 shared claims)
- Secondary endpoints: F1 (6 shared claims), F3 (2 shared claims), F4 (4 shared claims), F5 (2 shared claims), F8 (1 shared claims)
- Population and setting: F1 (1 shared claims), F3 (8 shared claims), F4 (1 shared claims), F11 (3 shared claims)
- The comparison: F1 (5 shared claims), F2 (2 shared claims), F3 (6 shared claims), F4 (1 shared claims), F6 (4 shared claims), F8 (2 shared claims), F10 (2 shared claims)
- Safety and tolerability: F1 (5 shared claims), F3 (2 shared claims), F4 (5 shared claims), F5 (3 shared claims)
- Design and conduct: F10 (9 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 11 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 303 | Paid |
| Trial aspects mapped | 15 | Free |
| Sources with links | 84 | Counts free |
| Speaker attribution for cited voices | 56 | Paid |

## Trial aspects

15 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Phase II (Feasibility study) Primary Outcome: Recruitment Rate | discussed | 6 | 6 |
| Primary endpoint: Phase III Primary Outcome: Organ Preservation | discussed | 43 | 19 |
| Secondary endpoints | discussed | 24 | 14 |
| Population and setting | discussed | 17 | 13 |
| The comparison | discussed | 40 | 25 |
| Safety and tolerability | discussed | 21 | 11 |
| Design and conduct | discussed | 20 | 14 |
| Patient-reported function and reasons to avoid competing treatments | discussed | 15 | 11 |
| Mesorectal-only fields, anal-canal sparing and planning quality | discussed | 18 | 7 |
| Dose escalation and brachytherapy as organ-preservation alternatives | discussed | 13 | 4 |
| Travel, radiation capacity, economics and sequence-dependent choices | discussed | 10 | 5 |
| Insufficient response, systemic treatment and biomarker-guidance questions | discussed | 12 | 7 |
| Preoperative versus definitive dose-response and radiobiological explanations | discussed | 16 | 1 |
| Guideline expectations, adoption, collaboration and evidence thresholds | discussed | 50 | 27 |
| Patient experience, public communication and support implications | discussed | 40 | 19 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 145 | 70 |
| Bluesky threads | 7 | 1 |
| X videos | 4 | 4 |
| YouTube | 2 | 2 |
| LinkedIn posts | 1 | 1 |
| Podcasts | 1 | 1 |
| Publications (primary source, cited for context) | not screened | 4 |
| Registry (primary source, cited for context) | not screened | 1 |

- Screened window: 2016-05-01 to 2026-10-29
- Cited window: 2016-05-13 to 2026-10-23
- Retrieved: 2026-10-31

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: STAR-TREC: Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?
- Registry: NCT02945566 (https://clinicaltrials.gov/study/NCT02945566)
- Study IDs: RG_15-011 · 2016-000862-49
- Sponsor: University of Birmingham
- Design: Phase 2/Phase 3 · interventional, randomized, parallel, phase2, phase3
- Status: Active, not recruiting
- Enrollment: 380 (estimated)
- Start: 2017-06-14 (actual)
- Primary completion: 2027-08 (estimated)
- Primary endpoint: Phase II (Feasibility study) Primary Outcome: Recruitment Rate (24 Months)
- Primary endpoint: Phase III Primary Outcome: Organ Preservation (30 Months from start day of (chemo)radiotherapy treatment.)
- Intervention: Standard TME surgery (procedure)
- Intervention: Long course concurrent chemoradiation with capecitabine and radiotherapy (drug)
- Intervention: Short course radiotherapy (radiation)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a question about evidence for low alpha/beta in rectal cancer and its possible implications for radiotherapy fractionation.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 94 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The report describes the sources reviewed for this edition, not all HCPs or all public discussion; discussion frequency and source numbers cannot establish clinician consensus.
- A complete text was unavailable for one review of local versus radical surgery. Its conclusions should not be treated as a comprehensive account of every underlying study.
- The directly included results paper concerns radiotherapy planning. Early clinical comparisons are conveyed through attributed commentary and a linked article summary; those sources do not establish mature 30-month clinical outcomes.
- Individual opinions, relayed presentations, institutional communication and patient anecdotes are different kinds of evidence. Reposting does not establish independent endorsement.
- Clinical roles are unstated or unconfirmed for several named authors. Descriptions of credentials, trial participation or leadership remain attributed to their sources, and do not increase the evidentiary weight of a view.
- Several video passages cannot be assigned to a named speaker from the spoken material. Captions, publisher descriptions and a named person elsewhere in the recording do not resolve those passages.
- Endpoint and population labels are inconsistent in some comments, including a speaker's 18% and approximately 25% statements and another speaker's locally advanced description and numerical characterization. They are preserved as statements, not silently corrected.
- Comparisons involving TREC, OPERA, WW2, NEO, TOWARd, RAPIDO and retrospective series retain their own settings and uncertainties. They are not STAR-TREC results or proof that their populations and regimens are interchangeable.
- Post dates and recruitment updates do not establish readout dates, changes of mind, current practice prevalence or confirmed guideline change.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-31: current edition

Last checked for new commentary 2026-10-31. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Deep (303 verified statements)
- Current edition: $1,950. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $3,400
- 6 months of weekly updates: $4,900
- 12 months of weekly updates: $6,800
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (40 now), at most $1,950; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/star-trec-nct02945566
- Agents: POST https://www.erudio.com/api/orders with {"report": "star-trec-nct02945566", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=star-trec-02945566

## Cite

Erudio Health. STAR-TREC (NCT02945566): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 31, 2026. https://www.erudio.com/reports/star-trec-nct02945566

## Machine access

- JSON: https://www.erudio.com/reports/star-trec-nct02945566.json
- Markdown: https://www.erudio.com/reports/star-trec-nct02945566.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "star-trec-02945566"}`